The text starts here.

News Release

FOR IMMEDIATE RELEASE
June 27, 2005

Eisai Announces Launch of Zonegran(R)(zonisamide), Treatment For Epilepsy In the U.K. and Germany

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) announced today that its U.K. subsidiary Eisai Ltd. (Headquarters: London, Managing Director: Paul Hooper) and German subsidiary Eisai GmbH (Headquarters: Frankfurt, President: Andreas N. Wiegand) has begun marketing Zonegran(R) hard capsules (zonisamide), an anti-epileptic drug for the adjunctive therapy of partial seizures in adults, in the U.K. and Germany, respectively. Product names are Zonegran(R)25mg, Zonegran(R)50mg, Zonegran(R)100mg both in the U.K. and in Germany.
U.K and Germany are the first countries in which Zonegran(R) will be marketed in Europe. In the future, Eisai aims at marketing Zonegran(R) across Europe.

Marketing authorization approval for Zonegran(R) was granted in March 2005. Following Aricept(R) and Pariet(R), Zonegran(R) is a strategic product for Eisai in order to expand its business opportunities in Europe. The Company will increase the number of MRs in the existing subsidiaries in Europe, and start-up new sales networks in newly advancing countries such as Italy. Further, the Company promotes the establishment of pharmaceutical business base across Europe to maximize product values of Zonegran(R) and plans to start development of Zonegran(R) for other indications such as monotherapy of partial seizures in adults.

Major characteristics of Zonegran(R) are that it has multiple mechanisms of action giving it a broad spectrum of pharmacological activity and its drug-drug interactions with other anti-epileptic drugs are minimal. Zonegran(R) was approved and launched in March 2000 in the U.S. for adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Eisai Inc., a subsidiary in the U.S., has been marketing the product since the end of April 2004.

Through marketing of Zonegran(R), Eisai will aim to strengthen its neurology product pipeline in Europe in order to fulfil patients' needs and contribute to further improve benefits with drug treatment.

Contacts:

Corporate Communications Department
Eisai Co., Ltd.
81-3-3817-5120

[Excerpt of Zonegran(R) follows]

<Note to the editor>
[Excerpt of Zonegran(R) in the U.K.]
Product name:Zonegran(R) hard capsules
Generic name:zonisamide
Pharmaceutical Forms and Strength:
Zonegran(R) 25mg: White/white capsule containing 25mg of zonisamide
Zonegran(R) 50mg: White/grey capsule containing 50mg of zonisamide
Zonegran(R) 100mg: White/red capsule containing 100mg of zonisamide
Applied Indication:Adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation
Dosage and Administration: Once or twice daily p.o., 300-500mg/day after titration.
Date of marketing authorization by European Commission:  March 10, 2005
Manufacturer: élan pharma Limited
Distribution: Eisai Ltd.

[Excerpt of Zonegran(R) in Germany]
Product name:Zonegran(R) hard capsules
Generic name:zonisamide
Pharmaceutical Forms and Strength:
Zonegran(R) 25mg: White/white capsule containing 25mg of zonisamide
Zonegran(R) 50mg: White/grey capsule containing 50mg of zonisamide
Zonegran(R) 100mg: White/red capsule containing 100mg of zonisamide
Applied Indication:Adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation
Dosage and Administration: Once or twice daily p.o., 300-500mg/day after titration.
Date of marketing authorization by European Commission:   March 10, 2005
Manufacturer: élan pharma Limited
Distribution: Eisai GmbH